**REGISTERED CHARITY NUMBER: 505256** 

Report of the Trustees and 

Unaudited Financial Statements 

for the Year Ended 30 April 2022 

for 

Kidneys For Life 

Paterson Brodie Limited Chartered Certified Accountants Cliveden Chambers Cliveden Place Longton Stoke-on-Trent Staffordshire ST3 4JB 



Kidneys For Life 

Contents of the Financial Statements for the Year Ended 30 April 2022 

|||**Page**||
|---|---|---|---|
|**Report of the Trustees**|1|to|4|
|**Independent Examiner's Report**||5||
|**Statement of Financial Activities**||6||
|**Balance Sheet**|7|to|8|
|**Notes to the Financial Statements**|9|to|18|
|**Detailed Statement of Financial Activities**|19|to|20|





## Kidneys For Life 

## Report of the Trustees for the Year Ended 30 April 2022 

The trustees present their report with the financial statements of the charity for the year ended 30 April 2022. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019). 

## **OBJECTIVES AND ACTIVITIES** 

## **Our mission** 

The strategic aim of Kidneys for Life fundraising for MINT (Manchester Institute for Nephrology & Transplantation) is the relief of renal related illnesses and the funding of research and education in renal disease, transplantation and allied fields together with the provision of direct patient amenities. 

## **Objectives** 

Kidneys for Life's objectives and main activities are to undertake charitable fundraising and the provision of those funds for the research and education in renal disease and allied fields and the provision of direct patient amenities. 

The trustees confirm that they have referred to the guidance contained in the Charity Commission's general guidance on public benefit when reviewing the Trust's aims and objectives and in planning future activities and setting the grant making policy for the year. 

## **Significant activities** 

The main activities currently carried out for the public benefit by the charity can be broadly categorised into the following:- 

- Research into renal related disease and associated diseases including transplantation 

- Direct patient amenities for those renal patients at Manchester Royal Infirmary, Royal Manchester Children's Hospital and Salford Royal Infirmary and their outlying satellite dialysis units 

The beneficiaries of our main activities are ultimately sufferers of renal related diseases and those at risk of developing this disease in the future together with their families/carers. There are increasing numbers of people in the UK with  some form of kidney disease and this is on the rise due to increased life expectancy and less healthier lifestyles. Developments in the care and treatment of those suffering from kidney disease has also the potential to relieve the huge burden of care often faced by the families and/or carers of sufferers. Our research and educational programmes funds researchers and renal staff who use these funds in their work to improve the lives of sufferers from kidney disease and related conditions, and their carers by developing therapies, potential medications and improvements in the personal care of sufferers. Any benefit received by researchers is purely incidental to the objects of our work. 

MINT is a member of the Association of Medical Research Charities and follows best practice in maintaining the independence of research funding and ensuring that sponsored researchers abide by best practice in research ethics and animal testing; our aim is to maximise the efficiency of the research programme whilst minimising the likelihood of harm to research volunteers and animals. 

## **How we work** 

The charity delivers its main aims in a number of ways including:- 

- Small Research Grants Scheme relating to renal diseases and transplantation 

- Post doctorate grants into renal disease and transplantation 

- Provision of a Renal Research Library available to all renal staff 

- Travel bursaries for renal staff to attend specialised training courses to further enhance their knowledge of renal diseases and transplantation 

- Educational grants to renal staff 

- Support for specialist conferences both in the UK and overseas including the Fabry Nephropathy Conference which is due to take place in Germany in May 2022. 

Academic ability and research potential are the primary determinants of our bursaries and grants and other factors such as nationality, ethnicity, gender, age, disability, sexual orientation and religion will not be taken into account. 

Page 1 



Kidneys For Life 

Report of the Trustees for the Year Ended 30 April 2022 

## **OBJECTIVES AND ACTIVITIES** 

In addition to this the charity also funds direct patient amenities for those suffering from renal disease or related diseases and this provision is not dependent upon factors such as nationality, ethnicity, gender, age, disability, sexual orientation and religion. 

## **ACHIEVEMENT AND PERFORMANCE Review of our achievements this financial year** 

The benefits of the charities work is the research into renal related diseases, education of renal staff, the dissemination of research findings, the development of new therapies and the funding of on-going research with the goal being to assist sufferers of renal related diseases, their carers and families. The trustees are pleased that the achievements and performance of the Charity as set out below with more detail on expenditure items, demonstrate our commitment to relieving the suffering of those with renal related diseases:- 

- Research Grant round 2021 - We invited applications for small research grants (to the value of £5,000) and after Trustee review we provided funding to the value of £57,361 (13 projects) 

- As all our Research Grants are now paid in arrears the total of outstanding grants is £149,416 

- In the last financial year we paid £ 32,805 to Research Projects with the breakdown as follows: 

- £4,407 was spent on Research Grant 2019- Development of a North West Big Data and Renal Cloud. Proof of 

- principle 

- £3,228 was spent on Research grant 2019 - The role of high vascular flow and vascular patterning in tissue engineered renal genesis 

- £5,000 was spent on Research Grant 2021 - Transdermal fluid removal in patients with fluid overload 

- £10,000 Research Grant 2019 - A new device to simplify minimal invasive pyeloplasty, earlier in the year £2,435 was returned to KFL due to a change in personnel at the host institution 

- £2,875 Research Grant 2019 - Can pre-operative testing be used to predict incisional hernia formation after renal transplantation 

- £1,845 was spent on Research Grant 2017- The impact of abdominal wall closure technique on incidence of incisional hernia in kidney transplantation 

- £1,587 was spent on Research Grant 2021 - Prediction Tool in Anti-GBM Disease 

- £1,667 was spent on Research Grant 2021 - Operate grant 

- £4,631 was spent on Research Grant 2017 Assessment of Pancreas Allografts Using Novel Magnetic Resonance Techniques 

- Travel Bursaries to the value of £1,213 were awarded to a variety of staff to attend training courses and conferences both here in the UK to further their education into renal related diseases. 

- We contributed £2,426 for patient amenities. 

- We supported a variety of Miscellaneous Grants totalling £13,340 

- We contributed £700 to Publication Grants 

- We made awards to help fund further education of renal nursing staff totalling £300 

More information of our research projects and researchers can be found on our website. 

## **FINANCIAL REVIEW Results** 

The total incoming resources for the year amount to £203,991 (2021 - £112,956). The charity expenditure for the financial year was £168,536 (2021 - £134,584). 

The current market value of the KFL investment portfolio at the year end was £290,601. 

Whilst the impact of Covid-19 still affected many of the scheduled Kidneys for Life fundraising activities, this financial year saw a significant improvement on the previous 12 month period. In particular, running & skydiving events generated far greater income than in previous years. We were also beneficiaries of a generous In Memory donation made by the family of a patient. We continued with a cautious approach to spend and indeed our spend on Travel Grants and Nurse Education grants was low - this is due to overseas conferences and training courses either not taking place or taking the hybrid format hence little travel expenditure was incurred. 

Page 2 



## Kidneys For Life 

## Report of the Trustees for the Year Ended 30 April 2022 

As the financial year came to a close large fundraising events were starting to take place and these should ensure an increase in income for the coming year. 

## **Investment policy and financial position** 

The charity has the power to make any investment which the Trustees see fit. Our investments are managed by Redmayne Bailey and we receive quarterly reports on the value of the Kidneys for Life portfolio. The spread of investments was agreed and a certain approach to risk continued. The charity believes it can generate income which together with investment income will allow the charity to continue for the foreseeable future with its level of charitable payments. 

## **Reserves policy** 

The events of recent years have had an effect upon the reserves of the Charity and the trustees are aware that it will be imperative that we maintain income to ensure that we are able to have in reserves funding for one year for our travel bursaries, nurse education grants, small research grants scheme and renal research library, £200k approximately. We endeavour to spend in excess of our income, save for restricted funds as detailed in Note 14, leaving sufficient reserves to fund ongoing research as mentioned. 

## **FUTURE PLANS** 

We will continue to carry out our main activities and our focus on future research, which by its nature is a slow process. Our focus will be: 

- to improve diagnosis and treatments for patients with kidney inflammation ( to stop progression to kidney failure) - to improve the treatment for patients on dialysis at home and in hospital dialysis units looking at improving phosphate and sodium clearance and water balance 

- to improve the lifespan of kidney transplants through clinical trials of new drugs and by preventing graft loss from recurrence of the primary kidney disease in the transplant 

## **STRUCTURE, GOVERNANCE AND MANAGEMENT** 

## **Governing document and legal status** 

The trust is governed by a trust deed dated 6th May 1976 and supplemental deeds of 15th September 1977 and 1st September 1983 and resolution of 4th August 1997, with the scheme further amended on 10th May 2000, 12 July 2007, 11th December 2015, 19th July 2019 and 22nd November 2019. 

## **Recruitment and appointment of new trustees** 

A trustee can propose the appointment of a trustee, on a proposal a vote shall be taken and approval shall be obtained through a simple majority. 

## **Organisation** 

The charity is administered from the Renal Unit at Manchester Royal Infirmary. The charity's objects and principal activity consists of charitable fundraising and the provisions of those funds for the advancement of research and provision of direct patient amenities for those suffering from kidney related diseases. 

Our trustees are unpaid and details of trustee expenses and any related party transactions are disclosed in note 5 to the accounts. 

## **Decision making** 

All decisions are made by a consensus of the trustees who represent the Manchester Royal Infirmary, Salford Royal Infirmary and Royal Manchester Children's Hospital. 

## **Trustee induction, training and development** 

New trustees are provided with an induction pack and are given initial training by the trustees and further training as and when required. 

Page 3 



Kidneys For Life 

## Report of the Trustees for the Year Ended 30 April 2022 

## **STRUCTURE, GOVERNANCE AND MANAGEMENT** 

## **Risk management** 

The Trustees review the major risks which the Charity faces at Trustee meetings. Trustee meetings take place on a quarterly basis and will continue to do so going forward. In addition to this the Trustees will convene additional meetings to discuss the financial position of the Charity. It is anticipated that by reviewing on a regular basis the Trustees will be able to appropriately adjust the reserves and charitable payments in line with the performance of the Charity. This will allow for the Trustees to provide sufficient resources in the event of adverse conditions. The Trustees have also examined other operational and business risks faced by the Charity and confirm that they have established systems to mitigate the immediate significant risks. 

## **REFERENCE AND ADMINISTRATIVE DETAILS Registered Charity number** 

505256 

## **Principal address** 

Renal Unit Manchester Royal Infirmary Oxford Road Manchester M13 9WL 

## **Trustees** 

|**Trustees**||
|---|---|
|Professor Titus Augustine|Consultant Surgeon|
|Professor Rachel Lennon|Consultant Paediatric Physician|
|Professor Sandip Mitra|Consultant Physician|
|Mr Afshin Tavakoli|Consultant Surgeon|
|Professor Phil Kalra|Consultant Physician|
|Dr Durga Kanigicherla|Consultant Nephrologist|
|Dr Amrit Kaur|Consultant in Paediatric Nephrology|
|Dr Smeeta Sinha|Consultant Nephrologist|
|Dr Michael Picton|Consultant Renal Physician|



## **Independent Examiner** 

Paul Scriven FCCA the Association of Chartered Certified Accountants Paterson Brodie Limited Chartered Certified Accountants Cliveden Chambers Cliveden Place Longton Stoke-on-Trent Staffordshire ST3 4JB 

Approved by order of the board of trustees on 6 January 2023 and signed on its behalf by: 


Mr Afshin Tavakoli - Trustee 

Page 4 



Ind
endeni Examiner'5 Re
ori to the Trusttts of
KidTre s For
Independent eAAminte5 re￿rt to tht trnsttts of KidDryS For tife
I rewrt to the Charity tNstees on my examinatK)n of the &counts of Kith￿$ For Life lthe T￿￿) for the ye8r end¢d
30 April ?0?2.
Rupon$ibilities And basis of report
A5 the charity trnsiees of the Tnjst you are resp)nsible for th¢ prepar*ion of the in XLxTrrknce with the
requirements of the Charitie5 Ad 2011 Ilhe Adl.
I rep)rt in resr*ct of my examination of the Twsfs ¥counts canied out under section 145 of the Act and in canying out
my examin*ion I havc folk)wed all applicable Direa1(￿S 8iven by tht Charity C￿MiSsion under stttion 14515Kbl of
the Affl.
IDdeptndeni euminer's stsiement
I ha%'e complded m) examination. I confirni no m*eriai m•ws have come ￿ my attention in connttthon with the
examinatiort giving mc cause w believe in any matrrial res
accountin8 records were ￿ k¢w in Yespea of the Tnw as wuirtd b). seaion 130 of the A¢L or
the arrounts do not accord with tlK)se records: or
Ihe accounts do rK)t comply with the applicable reqUi￿￿￿ts concerning the fonn and content of accounts set out
in the Charities (Accounts and Rew)rtsl Regul￿10Th5 ?IK18 Imher than any requirement that the accounts give a
tnJ¢ ond fa¢r view which is not a matter considcred as part of an inder*ndeTrt exatnination.
I have concerns and have come auoss Th) oth¢r m•*rs irt ¢onne¢tion with the ¢wnin￿lOn w whi¢h 8lleniion should
drdwn in this rep)rt in orderto eTthle a prDper under5tsnding of the xcounts ￿ be ￿aChed.
Paul ScriNen FCCA
lh¢ Associaiion of Chartertd Certified Accountants
Pat¢TSOn Brcrtlie Limi*d
Chartered Certified Aecoyntants
Cliveden Chamber5
Cliveden Place
Longton
Stoke-on-Trrnt
Ststrordshire
ST3 4JB
6 January 2023
Page 5

## Kidneys For Life 

## Statement of Financial Activities for the Year Ended 30 April 2022 

|Unrestricted<br>funds<br>Notes<br>£<br>**INCOME AND ENDOWMENTS FROM**<br>Donations and legacies<br>2<br>79,536<br>Other trading activities<br>3<br>67,155<br>Investment income<br>4<br>2,453<br>**Total**<br>149,144<br>**EXPENDITURE ON**<br>Raising funds<br>62,590<br>**Charitable activities**<br>Expenditure on Charitable Activities<br>68,292<br>**Total**<br>130,882<br>Net gains/(losses) on investments<br>(9,431)<br>**NET INCOME**<br>8,831<br>**Transfers between funds**<br>14<br>(55,929)<br>**Net movement in funds**<br>(47,098)<br>**RECONCILIATION OF FUNDS**<br>**Total funds brought forward**<br>139,638<br>**TOTAL FUNDS CARRIED FORWARD**<br>92,540|Restricted<br>funds<br>£<br>22,238<br>32,609<br>-<br>54,847<br>21<br>37,633<br>37,654<br>-<br>17,193<br>55,929<br>73,122<br>174,339<br>247,461|30.4.22<br>Total<br>funds<br>£<br>101,774<br>99,764<br>2,453<br>203,991<br>62,611<br>105,925<br>168,536<br>(9,431)<br>26,024<br>-<br>26,024<br>313,977<br>340,001|30.4.21<br>Total<br>funds<br>£<br>80,669<br>30,567<br>1,720|
|---|---|---|---|
||||112,956|
||||66,350<br>68,234|
||||134,584|
||||55,783|
||||34,155<br>-|
||||34,155<br>279,822|
||||313,977|



## **CONTINUING OPERATIONS** 

All income and expenditure has arisen from continuing activities. 

The notes form part of these financial statements 

Page 6 



## Kidneys For Life 

|Balance Sheet<br>30 April 2022<br>Unrestricted<br>funds<br>Notes<br>£<br>**FIXED ASSETS**<br>Investments<br>10<br>114,537<br>**CURRENT ASSETS**<br>Stocks<br>11<br>1,496<br>Debtors<br>12<br>2,977<br>Cash at bank and in hand<br>71,802<br>76,275<br>**CREDITORS**<br>Amounts falling due within one year<br>13<br>(98,272)<br>**NET CURRENT ASSETS**<br>(21,997)<br>**TOTAL ASSETS LESS CURRENT**<br>**LIABILITIES**<br>92,540<br>**NET ASSETS**<br>92,540|Restricted<br>funds<br>£<br>176,064<br>-<br>1,089<br>70,598<br>71,687<br>(290)<br>71,397<br>247,461<br>247,461|30.4.22<br>Total<br>funds<br>£<br>290,601<br>1,496<br>4,066<br>142,400<br>147,962<br>(98,562)<br>49,400<br>340,001<br>340,001|30.4.21<br>Total<br>funds<br>£<br>299,338<br>1,533<br>6,607<br>35,329<br>43,469<br>(28,830)<br>14,639<br>313,977<br>313,977|
|---|---|---|---|



The notes form part of these financial statements 

continued... 

Page 7 



## Kidneys For Life 

## Balance Sheet - continued 30 April 2022 

|**FUNDS**<br>14<br>Unrestricted funds:<br>General fund<br>Revaluation Fund<br>Restricted funds:<br>Children's Renal Fund<br>Bladder Exstrophy Fund<br>Grants Awarded Not Yet Taken<br>Kidney Info Network<br>Urology Sports Day<br>Tameside Dialysis<br>Adult Transplant Games<br>Polycystic kidney disease research<br>Cheshire and Merseyside Kidney Information<br>network Recipe<br>**TOTAL FUNDS**|53,260<br>39,280<br>92,540<br>69,071<br>20,452<br>149,416<br>285<br>3,792<br>1,102<br>1,000<br>1,998<br>345<br>247,461<br>340,001|90,620<br>49,018|
|---|---|---|
|||139,638|
|||36,443<br>3,427<br>126,292<br>285<br>3,792<br>1,102<br>1,000<br>1,998<br>-|
|||174,339|
||||
|||313,977|



The financial statements were approved by the Board of Trustees and authorised for issue on 6 January 2023 and were signed on its behalf by: 


Mr Afshin Tavakoli - Trustee 


Professor Rachel Lennon - Trustee 

The notes form part of these financial statements 

Page 8 



Kidneys For Life 

## Notes to the Financial Statements for the Year Ended 30 April 2022 

## **1. ACCOUNTING POLICIES** 

## **Basis of preparing the financial statements** 

The financial statements of the charity, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Charities Act 2011. The financial statements have been prepared under the historical cost convention, with the exception of investments which are included at market value, as modified by the revaluation of certain assets. 

## **Financial reporting standard 102 - reduced disclosure exemptions** 

The charity has taken advantage of the following disclosure exemptions in preparing these financial statements, as permitted by FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland': 

- the requirements of Section 7 Statement of Cash Flows. 

## **Income** 

All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably.The following specific policies are applied to particular categories of income: 

Voluntary income is received by way of grants, donations and gifts and is included in full in the statement of financial activities when receivable. Grants, where entitlement is not conditional on the delivery of a specific performance by the charity are recognised when the charity becomes unconditionally entitled to the grant. 

Investment income is included when receivable. 

Fundraising events income includes all income from both Kidneys for Life led events and those undertaken by supporters. 

## **Expenditure** 

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Expenditure includes any irrecoverable VAT which cannot be fully recovered and is charged against the expenditure to which it relates. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources. 

Cost of raising funds comprise of the costs associated with attracting voluntary income and the costs of trading for fundraising purposes. 

Charitable expenditure comprise of those costs incurred by the charity in the delivering of its activities and providing grants. 

Governance costs include those costs associated with the constitutional and statutory requirements of the Charity and include the accountancy fee and other overhead and support costs. 

## **Tangible fixed assets** 

Fixed assets (excluding investments) are stated at cost less accumulated depreciation. The costs of minor additions or those costing below £1,000 are not capitalised. Depreciation is provided at rates calculated to write off the cost of each asset over its expected useful life, which in all cases is estimated at 5 years. 

continued... 

Page 9 



Kidneys For Life 

## Notes to the Financial Statements - continued for the Year Ended 30 April 2022 

## **1. ACCOUNTING POLICIES - continued** 

## **Stocks** 

Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items. 

## **Taxation** 

The charity is exempt from tax on its charitable activities. 

## **Fund accounting** 

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees. Unrestricted funds include a revaluation reserve representing the restatement of investment assets at current value. 

Designated funds are unrestricted funds earmarked by the management committee for particular purposes. 

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or through the terms of an appeal. 

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements. 

## **Pension costs and other post-retirement benefits** 

The Charity operates a defined contribution pension scheme. Contributions payable to the pension scheme are charged to the Statement of Financial Activities in the period to which they relate. 

## **2. DONATIONS AND LEGACIES** 

|**DONATIONS AND LEGACIES**|||
|---|---|---|
||30.4.22|30.4.21|
||£|£|
|Donations|101,774|80,669|



Donations includes £22,238 (2021 - £16,839) relating to the restricted funds for Bladder Exstrophy, Children's Renal Fund (formerly Child Transplant Games), Urology Sports Day, Tameside Dialysis, Adult Games, Polycystic Kidney Disease Research and CAMKIN recipe. 

## **3. OTHER TRADING ACTIVITIES** 

|**OTHER TRADING ACTIVITIES**|||
|---|---|---|
||30.4.22|30.4.21|
||£|£|
|Fundraising events|99,764|30,567|



Fundraising includes £32,609 (2021 - £55) relating to the restricted funds for Children's Renal Fund (formerly Child Transplant Games). 

continued... 

Page 10 



## Kidneys For Life 

## Notes to the Financial Statements - continued for the Year Ended 30 April 2022 

## **4. INVESTMENT INCOME** 

|**INVESTMENT INCOME**|||
|---|---|---|
||30.4.22|30.4.21|
||£|£|
|Dividend and stock income|2,437|1,706|
|Deposit account interest|16|14|
||2,453|1,720|



## **5. TRUSTEES' REMUNERATION AND BENEFITS** 

There were no trustees' remuneration or other benefits for the year ended 30 April 2022 nor for the year ended 30 April 2021. 

## **Trustees' expenses** 

There were no trustees' expenses paid or travel bursaries awarded during the year ended 30 April 2022 nor for the year ended 30 April 2021. 

## **6. STAFF COSTS** 

The average monthly number of employees during the year was as follows: 

||30.4.22|30.4.21|
|---|---|---|
|Staff|1|1|



No employees received emoluments in excess of £60,000. 

## **7. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES** 

|Unrestricted<br>funds<br>£<br>**INCOME AND ENDOWMENTS FROM**<br>Donations and legacies<br>63,830<br>Other trading activities<br>30,512<br>Investment income<br>1,720<br>**Total**<br>96,062<br>**EXPENDITURE ON**<br>Raising funds<br>66,184<br>**Charitable activities**<br>Expenditure on Charitable Activities<br>44,115<br>**Total**<br>110,299<br>Net gains on investments<br>55,783<br>**NET INCOME/(EXPENDITURE)**<br>41,546<br>**Transfers between funds**<br>20,578|Restricted<br>funds<br>£<br>16,839<br>55<br>-<br>16,894<br>166<br>24,119<br>24,285<br>-<br>(7,391)<br>(20,578)|Total<br>funds<br>£<br>80,669<br>30,567<br>1,720|
|---|---|---|
|||112,956|
|||66,350<br>68,234|
|||134,584|
|||55,783|
|||34,155<br>-|



continued... 

Page 11 



## Kidneys For Life 

## Notes to the Financial Statements - continued for the Year Ended 30 April 2022 

|**7.**<br>**COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES - continued**<br>Unrestricted<br>Restricted<br>funds<br>funds<br>£<br>£<br>**Net movement in funds**<br>62,124<br>(27,969)<br>**RECONCILIATION OF FUNDS**<br>**Total funds brought forward**<br>77,514<br>202,308<br>**TOTAL FUNDS CARRIED FORWARD**<br>139,638<br>174,339<br>**8.**<br>**NET GAINS/(LOSSES) ON INVESTMENTS**<br>Realised net gains on investments<br>30.4.22<br>£<br>Share dealing - gains<br>307<br>Share dealing - losses<br>-<br>307<br>Unrealised (loss)/gain on revaluation<br>(9,738)<br>(9,431)<br>Realised net losses/gains are stated after deducting dealing charges.<br>Total transaction charges for the year are as follows:<br>£<br>Dealing charges<br>120<br>**9.**<br>**TANGIBLE FIXED ASSETS**<br>Office<br>Computer<br>equipment<br>equipment<br>£<br>£<br>**COST**<br>At 1 May 2021 and 30 April 2022<br>1,518<br>13,535<br>**DEPRECIATION**<br>At 1 May 2021 and 30 April 2022<br>1,518<br>13,535<br>**NET BOOK VALUE**<br>At 30 April 2022<br>-<br>-<br>At 30 April 2021<br>-<br>-|**7.**<br>**COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES - continued**<br>Unrestricted<br>Restricted<br>funds<br>funds<br>£<br>£<br>**Net movement in funds**<br>62,124<br>(27,969)<br>**RECONCILIATION OF FUNDS**<br>**Total funds brought forward**<br>77,514<br>202,308<br>**TOTAL FUNDS CARRIED FORWARD**<br>139,638<br>174,339<br>**8.**<br>**NET GAINS/(LOSSES) ON INVESTMENTS**<br>Realised net gains on investments<br>30.4.22<br>£<br>Share dealing - gains<br>307<br>Share dealing - losses<br>-<br>307<br>Unrealised (loss)/gain on revaluation<br>(9,738)<br>(9,431)<br>Realised net losses/gains are stated after deducting dealing charges.<br>Total transaction charges for the year are as follows:<br>£<br>Dealing charges<br>120<br>**9.**<br>**TANGIBLE FIXED ASSETS**<br>Office<br>Computer<br>equipment<br>equipment<br>£<br>£<br>**COST**<br>At 1 May 2021 and 30 April 2022<br>1,518<br>13,535<br>**DEPRECIATION**<br>At 1 May 2021 and 30 April 2022<br>1,518<br>13,535<br>**NET BOOK VALUE**<br>At 30 April 2022<br>-<br>-<br>At 30 April 2021<br>-<br>-|**7.**<br>**COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES - continued**<br>Unrestricted<br>Restricted<br>funds<br>funds<br>£<br>£<br>**Net movement in funds**<br>62,124<br>(27,969)<br>**RECONCILIATION OF FUNDS**<br>**Total funds brought forward**<br>77,514<br>202,308<br>**TOTAL FUNDS CARRIED FORWARD**<br>139,638<br>174,339<br>**8.**<br>**NET GAINS/(LOSSES) ON INVESTMENTS**<br>Realised net gains on investments<br>30.4.22<br>£<br>Share dealing - gains<br>307<br>Share dealing - losses<br>-<br>307<br>Unrealised (loss)/gain on revaluation<br>(9,738)<br>(9,431)<br>Realised net losses/gains are stated after deducting dealing charges.<br>Total transaction charges for the year are as follows:<br>£<br>Dealing charges<br>120<br>**9.**<br>**TANGIBLE FIXED ASSETS**<br>Office<br>Computer<br>equipment<br>equipment<br>£<br>£<br>**COST**<br>At 1 May 2021 and 30 April 2022<br>1,518<br>13,535<br>**DEPRECIATION**<br>At 1 May 2021 and 30 April 2022<br>1,518<br>13,535<br>**NET BOOK VALUE**<br>At 30 April 2022<br>-<br>-<br>At 30 April 2021<br>-<br>-|**7.**<br>**COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES - continued**<br>Unrestricted<br>Restricted<br>funds<br>funds<br>£<br>£<br>**Net movement in funds**<br>62,124<br>(27,969)<br>**RECONCILIATION OF FUNDS**<br>**Total funds brought forward**<br>77,514<br>202,308<br>**TOTAL FUNDS CARRIED FORWARD**<br>139,638<br>174,339<br>**8.**<br>**NET GAINS/(LOSSES) ON INVESTMENTS**<br>Realised net gains on investments<br>30.4.22<br>£<br>Share dealing - gains<br>307<br>Share dealing - losses<br>-<br>307<br>Unrealised (loss)/gain on revaluation<br>(9,738)<br>(9,431)<br>Realised net losses/gains are stated after deducting dealing charges.<br>Total transaction charges for the year are as follows:<br>£<br>Dealing charges<br>120<br>**9.**<br>**TANGIBLE FIXED ASSETS**<br>Office<br>Computer<br>equipment<br>equipment<br>£<br>£<br>**COST**<br>At 1 May 2021 and 30 April 2022<br>1,518<br>13,535<br>**DEPRECIATION**<br>At 1 May 2021 and 30 April 2022<br>1,518<br>13,535<br>**NET BOOK VALUE**<br>At 30 April 2022<br>-<br>-<br>At 30 April 2021<br>-<br>-||Total<br>funds<br>£|
|---|---|---|---|---|---|
||||||34,155<br>279,822|
||||||313,977|
|||||||
||||30.4.22||30.4.21|
||||£||£|
||||307||14,428|
||||-||(4,581)|
|||||||
|||||||
||||307||9,847|
||||(9,738)||45,936|
|||||||
|||||||
||||(9,431)||55,783|
|||||||
|||||||
||||£||£|
||||120||480|
|||||||
|||Computer<br>equipment<br>£<br>13,535<br>13,535<br>-<br>-|||Totals<br>£<br>15,053<br>15,053<br>-<br>-|



continued... 

Page 12 



Kidneys For Life 

## Notes to the Financial Statements - continued for the Year Ended 30 April 2022 

## **10. FIXED ASSET INVESTMENTS** 

Fixed asset investments consist of the Kidneys for Life Portfolio. The Portfolio is valued at current market value at the year end date 

|**11.**|**STOCKS**|||
|---|---|---|---|
|||30.4.22|30.4.21|
|||£|£|
||Finished goods|1,496|1,533|
|**12.**|**DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**|||
|||30.4.22|30.4.21|
|||£|£|
||Other debtors|2,543|2,017|
||Provision for tax rebate|470|2,446|
||Prepayments|1,053|2,144|
|||4,066|6,607|
|**13.**|**CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**|||
|||30.4.22|30.4.21|
|||£|£|
||Trade creditors|56,973|20,229|
||Taxation and social security|(28)|171|
||Other creditors|41,617|8,430|
|||98,562|28,830|



continued... 

Page 13 



## Kidneys For Life 

## Notes to the Financial Statements - continued for the Year Ended 30 April 2022 

## **14. MOVEMENT IN FUNDS** 

|**Unrestricted funds**<br>General fund<br>Revaluation Fund<br>Designated Fund<br>**Restricted funds**<br>Children's Renal Fund<br>Bladder Exstrophy Fund<br>Grants Awarded Not Yet Taken<br>Kidney Info Network<br>Urology Sports Day<br>Tameside Dialysis<br>Adult Transplant Games<br>Polycystic kidney disease research<br>Cheshire and Merseyside Kidney<br>Information network Recipe<br>**TOTAL FUNDS**<br>Net movement in funds, included in the above are as<br>**Unrestricted funds**<br>General fund<br>Revaluation Fund<br>Designated Fund<br>**Restricted funds**<br>Children's Renal Fund<br>Bladder Exstrophy Fund<br>Grants Awarded Not Yet Taken<br>Cheshire and Merseyside Kidney<br>Information network Recipe<br>**TOTAL FUNDS**|At 1.5.21<br>£<br>90,620<br>49,018<br>-<br>139,638<br>36,443<br>3,427<br>126,292<br>285<br>3,792<br>1,102<br>1,000<br>1,998<br>-<br>174,339<br>313,977<br>follows:<br>Incoming<br>resources<br>£<br>149,144<br>-<br>-<br>149,144<br>34,908<br>19,594<br>-<br>345<br>54,847<br>203,991|Net<br>movement<br>in funds<br>£<br>34,183<br>(9,738)<br>(15,614)<br>8,831<br>32,628<br>17,025<br>(32,805)<br>-<br>-<br>-<br>-<br>-<br>345<br>17,193<br>26,024<br>Resources<br>expended<br>£<br>(115,268)<br>-<br>(15,614)<br>(130,882)<br>(2,280)<br>(2,569)<br>(32,805)<br>-<br>(37,654)<br>(168,536)|Transfers<br>between<br>At<br>funds<br>30.4.22<br>£<br>£<br>(71,543)<br>53,260<br>-<br>39,280<br>15,614<br>-<br>(55,929)<br>92,540<br>-<br>69,071<br>-<br>20,452<br>55,929<br>149,416<br>-<br>285<br>-<br>3,792<br>-<br>1,102<br>-<br>1,000<br>-<br>1,998<br>-<br>345<br>55,929<br>247,461<br>-<br>340,001<br>Gains and<br>Movement<br>losses<br>in funds<br>£<br>£<br>307<br>34,183<br>(9,738)<br>(9,738)<br>-<br>(15,614)<br>(9,431)<br>8,831<br>-<br>32,628<br>-<br>17,025<br>-<br>(32,805)<br>-<br>345<br>-<br>17,193<br>(9,431)<br>26,024|
|---|---|---|---|



continued... 

Page 14 



Kidneys For Life 

## Notes to the Financial Statements - continued for the Year Ended 30 April 2022 

## **14. MOVEMENT IN FUNDS - continued** 

## **Comparatives for movement in funds** 

|**Unrestricted funds**<br>General fund<br>Revaluation Fund<br>Designated Fund<br>**Restricted funds**<br>Children's Renal Fund<br>Bladder Exstrophy Fund<br>Grants Awarded Not Yet Taken<br>Kidney Info Network<br>Urology Sports Day<br>Tameside Dialysis<br>Adult Transplant Games<br>Polycystic kidney disease research<br>**TOTAL FUNDS**|At 1.5.20<br>£<br>74,438<br>3,076<br>-<br>77,514<br>23,320<br>-<br>173,698<br>401<br>3,912<br>977<br>-<br>-<br>202,308<br>279,822|Net<br>movement<br>in funds<br>£<br>(326)<br>45,936<br>(4,064)<br>41,546<br>13,123<br>421<br>(23,822)<br>(116)<br>(120)<br>125<br>1,000<br>1,998<br>(7,391)<br>34,155|Transfers<br>between<br>funds<br>£<br>16,508<br>6<br>4,064<br>20,578<br>-<br>3,006<br>(23,584)<br>-<br>-<br>-<br>-<br>-<br>(20,578)<br>-|At<br>30.4.21<br>£<br>90,620<br>49,018<br>-|
|---|---|---|---|---|
|||||139,638<br>36,443<br>3,427<br>126,292<br>285<br>3,792<br>1,102<br>1,000<br>1,998|
|||||174,339|
|||||313,977|



Comparative net movement in funds, included in the above are as follows: 

|**Unrestricted funds**<br>General fund<br>Revaluation Fund<br>Designated Fund<br>**Restricted funds**<br>Children's Renal Fund<br>Bladder Exstrophy Fund<br>Grants Awarded Not Yet Taken<br>Kidney Info Network<br>Urology Sports Day<br>Tameside Dialysis<br>Adult Transplant Games<br>Polycystic kidney disease research<br>**TOTAL FUNDS**|Incoming<br>resources<br>£<br>96,062<br>-<br>-<br>96,062<br>13,348<br>421<br>-<br>-<br>-<br>125<br>1,000<br>2,000<br>16,894<br>112,956|Resources<br>expended<br>£<br>(106,235)<br>-<br>(4,064)<br>(110,299)<br>(225)<br>-<br>(23,822)<br>(116)<br>(120)<br>-<br>-<br>(2)<br>(24,285)<br>(134,584)|Gains and<br>Movement<br>losses<br>in funds<br>£<br>£<br>9,847<br>(326)<br>45,936<br>45,936<br>-<br>(4,064)<br>55,783<br>41,546<br>-<br>13,123<br>-<br>421<br>-<br>(23,822)<br>-<br>(116)<br>-<br>(120)<br>-<br>125<br>-<br>1,000<br>-<br>1,998<br>-<br>(7,391)<br>55,783<br>34,155|Gains and<br>Movement<br>losses<br>in funds<br>£<br>£<br>9,847<br>(326)<br>45,936<br>45,936<br>-<br>(4,064)<br>55,783<br>41,546<br>-<br>13,123<br>-<br>421<br>-<br>(23,822)<br>-<br>(116)<br>-<br>(120)<br>-<br>125<br>-<br>1,000<br>-<br>1,998<br>-<br>(7,391)<br>55,783<br>34,155|
|---|---|---|---|---|
|||||41,546<br>13,123<br>421<br>(23,822)<br>(116)<br>(120)<br>125<br>1,000<br>1,998|
|||||(7,391)|
|||||34,155|



Page 15 

continued... 



Kidneys For Life 

## Notes to the Financial Statements - continued for the Year Ended 30 April 2022 

## **14. MOVEMENT IN FUNDS - continued** 

A current year 12 months and prior year 12 months combined position is as follows: 

|**Unrestricted funds**<br>General fund<br>Revaluation Fund<br>Designated Fund<br>**Restricted funds**<br>Children's Renal Fund<br>Bladder Exstrophy Fund<br>Grants Awarded Not Yet Taken<br>Kidney Info Network<br>Urology Sports Day<br>Tameside Dialysis<br>Adult Transplant Games<br>Polycystic kidney disease research<br>Cheshire and Merseyside Kidney<br>Information network Recipe<br>**TOTAL FUNDS**|At 1.5.20<br>£<br>74,438<br>3,076<br>-<br>77,514<br>23,320<br>-<br>173,698<br>401<br>3,912<br>977<br>-<br>-<br>-<br>202,308<br>279,822|Net<br>movement<br>in funds<br>£<br>33,857<br>36,198<br>(19,678)<br>50,377<br>45,751<br>17,446<br>(56,627)<br>(116)<br>(120)<br>125<br>1,000<br>1,998<br>345<br>9,802<br>60,179|Transfers<br>between<br>funds<br>£<br>(55,035)<br>6<br>19,678<br>(35,351)<br>-<br>3,006<br>32,345<br>-<br>-<br>-<br>-<br>-<br>-<br>35,351<br>-|At<br>30.4.22<br>£<br>53,260<br>39,280<br>-|
|---|---|---|---|---|
|||||92,540<br>69,071<br>20,452<br>149,416<br>285<br>3,792<br>1,102<br>1,000<br>1,998<br>345|
|||||247,461|
|||||340,001|



Page 16 

continued... 



Kidneys For Life 

## Notes to the Financial Statements - continued for the Year Ended 30 April 2022 

## **14. MOVEMENT IN FUNDS - continued** 

A current year 12 months and prior year 12 months combined net movement in funds, included in the above are as follows: 

|**Unrestricted funds**<br>General fund<br>Revaluation Fund<br>Designated Fund<br>**Restricted funds**<br>Children's Renal Fund<br>Bladder Exstrophy Fund<br>Grants Awarded Not Yet Taken<br>Kidney Info Network<br>Urology Sports Day<br>Tameside Dialysis<br>Adult Transplant Games<br>Polycystic kidney disease research<br>Cheshire and Merseyside Kidney<br>Information network Recipe<br>**TOTAL FUNDS**|Incoming<br>resources<br>£<br>245,206<br>-<br>-<br>245,206<br>48,256<br>20,015<br>-<br>-<br>-<br>125<br>1,000<br>2,000<br>345<br>71,741<br>316,947|Resources<br>expended<br>£<br>(221,503)<br>-<br>(19,678)<br>(241,181)<br>(2,505)<br>(2,569)<br>(56,627)<br>(116)<br>(120)<br>-<br>-<br>(2)<br>-<br>(61,939)<br>(303,120)|Gains and<br>Movement<br>losses<br>in funds<br>£<br>£<br>10,154<br>33,857<br>36,198<br>36,198<br>-<br>(19,678)<br>46,352<br>50,377<br>-<br>45,751<br>-<br>17,446<br>-<br>(56,627)<br>-<br>(116)<br>-<br>(120)<br>-<br>125<br>-<br>1,000<br>-<br>1,998<br>-<br>345<br>-<br>9,802<br>46,352<br>60,179|
|---|---|---|---|



## **Purpose of funds** 

## Designated Fund 

The purpose of the designated funds is to provide for travel bursaries, upkeep of the renal library, small grants scheme and educational grants for renal staff and direct patient amenities. 

## Revaluation Fund 

The revaluation fund recognises the amount by which the investments exceed their historical cost. 

## Bladder Exstrophy Fund 

This fund is for use by the Bladder Exstrophy Team at Royal Manchester Children's Hospital to facilitate their annual Christmas Party, medical equipment and research funding. 

## Children's Renal Fund (formerly Child Transplant Games) 

This fund is for use by the Children's Renal Team at Royal Manchester Children's Hospital to facilitate the attendance of the Manchester Children's Transplant Games Team at the British Transplant Games each year, purchase of medical equipment, patient amenities for the wards and staff education. 

## Kidney Info Network 

We work with GMKIN (Greater Manchester Kidney Information Network) to provide a social media presence for kidney patients in the North West. The fund is for use in maintaining this presence. 

continued... 

Page 17 



Kidneys For Life 

Notes to the Financial Statements - continued for the Year Ended 30 April 2022 

## **14. MOVEMENT IN FUNDS - continued** 

## **Purpose of funds - continued** 

## Tameside Dialysis Fund 

Kidneys for Life received a donation in memory of a Tameside Dialysis patient and with the request that these funds be spent at Tameside Dialysis Unit. The staff at the Unit are aware of this donation and will communicate with Kidneys for Life when they decide how they would like this money to be spent. 

## Urology Sports Day Fund 

The Urology Sports Day was set up by Dr Anju Goyal and was paid for using funds from the Urology Fund which Kidneys for Life administers as per the MOU on their behalf. It is to be used to facilitate an annual event. 

## Adult Games Fund 

Kidneys for Life received a donation with the request that these funds be spent on adult games. 

## Polycystic Kidney Disease Research Fund 

Kidneys for Life received a donation with the request that these funds be spent on polycystic kidney disease research. 

Cheshire and Merseyside Kidney Information Network Recipe Fund 

Received donations to fund a special renal recipe book. 

## **15. RELATED PARTY DISCLOSURES** 

There were no related party transactions for the year ended 30 April 2022, except for a transaction of £350 with a company Professor Phil Kalra is a member of and has a position of control/management. 

All trustees remove themselves from any decision if they have a related party connection with the company being discussed. 

## **16. FABRY NEPHROPATHY CONFERENCE FUND** 

A separate bank account was opened to facilitate the income and expenditure for the bi-annual conference. The next conference is scheduled to take place in Germany in May 2022. The movement on the account is shown below. The end balance equating to the balance on the bank account at the 30th April 2022. 

||Balance at|||Balance at|
|---|---|---|---|---|
||1.5.21|Incoming|Outgoing|30.4.22|
||£|£|£|£|
|Movement to date|61,784|219,827|43,529|238,082|
||||||



The Fabry bank account was owed £32,740 by Kidneys for life at the 30th April 2022. 

Page 18 



## Kidneys For Life 

|**INCOME AND ENDOWMENTS**<br>**Donations and legacies**<br>Donations<br>**Other trading activities**<br>Fundraising events<br>**Investment income**<br>Dividend and stock income<br>Deposit account interest<br>**Total incoming resources**<br>**EXPENDITURE**<br>**Raising donations and legacies**<br>Wages<br>Postage and miscellaneous<br>Promotional costs<br>Event costs<br>Travel costs<br>Card fees<br>Christmas cards<br>**Charitable activities**<br>Grant management<br>Bladder Exstrophy Fund<br>Miscellaneous grants<br>Ward and medical equipment<br>Travel & conference bursaries<br>Small research grants<br>Nurse education<br>Patient support<br>Publication grants<br>**Support costs**<br>**Governance costs**<br>Governance management<br>Insurance<br>Carried forward|Detailed Statement of Financial Activities<br>for the Year Ended 30 April 2022<br>30.4.22<br>30.4.21<br>£<br>£<br>101,774<br>80,669<br>99,764<br>30,567<br>2,437<br>1,706<br>16<br>14<br>2,453<br>1,720<br>203,991<br>112,956<br>34,190<br>48,169<br>2,069<br>4,111<br>10,600<br>5,877<br>12,478<br>4,198<br>74<br>270<br>1,062<br>961<br>2,138<br>2,764<br>62,611<br>66,350<br>17,304<br>16,502<br>2,345<br>-<br>13,340<br>3,535<br>118<br>100<br>1,213<br>-<br>32,805<br>23,822<br>300<br>300<br>2,426<br>310<br>700<br>-<br>70,551<br>44,569<br>12,360<br>11,787<br>607<br>677<br>12,967<br>12,464|Detailed Statement of Financial Activities<br>for the Year Ended 30 April 2022<br>30.4.22<br>30.4.21<br>£<br>£<br>101,774<br>80,669<br>99,764<br>30,567<br>2,437<br>1,706<br>16<br>14<br>2,453<br>1,720<br>203,991<br>112,956<br>34,190<br>48,169<br>2,069<br>4,111<br>10,600<br>5,877<br>12,478<br>4,198<br>74<br>270<br>1,062<br>961<br>2,138<br>2,764<br>62,611<br>66,350<br>17,304<br>16,502<br>2,345<br>-<br>13,340<br>3,535<br>118<br>100<br>1,213<br>-<br>32,805<br>23,822<br>300<br>300<br>2,426<br>310<br>700<br>-<br>70,551<br>44,569<br>12,360<br>11,787<br>607<br>677<br>12,967<br>12,464|
|---|---|---|
||||
|||1,720|
|||112,956<br>48,169<br>4,111<br>5,877<br>4,198<br>270<br>961<br>2,764|
|||66,350<br>16,502<br>-<br>3,535<br>100<br>-<br>23,822<br>300<br>310<br>-|
|||44,569<br>11,787<br>677<br>12,464|



This page does not form part of the statutory financial statements 

Page 19 



## Kidneys For Life 

## Detailed Statement of Financial Activities 

|Detailed Statement of Financial Activities|||
|---|---|---|
|for the Year Ended 30 April 2022|||
||30.4.22|30.4.21|
||£|£|
|**Governance costs**|||
|Brought forward|12,967|12,464|
|Telephone|848|1,168|
|Accountancy|3,122|2,870|
|Investment management|2,795|2,789|
|Office Equipment & Computer Maintenance|||
|and Updates|15,642|4,374|
||35,374|23,665|
|Total resources expended|168,536|134,584|
|**Net income/(expenditure) before gains and**|||
|**losses**|35,455|(21,628)|
|**Realised recognised gains and losses**|||
|Realised gains/(losses) on fixed asset investments|307|9,847|
|Profit/(loss) on revaluation of investments|(9,738)|45,936|
|**Net income**|26,024|34,155|



This page does not form part of the statutory financial statements 

Page 20 

